Karabo Ramatapa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karabo Ramatapa has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ivy Rukasha
Department of Pathology, School of Medicine, University of Limpopo, Sovenga 0727, Limpopo, South Africa
2 shared publications - Mduduzi Paul Mokoena
University of Limpopo
2 shared publications - Saheed Sabiu
Durban University of Technology
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by MDPI AG in Preprints.org
Recent Advances in Aloe vera as a Therapeutic Strategy Against Drug-Resistant Pseudomonas aeruginosa: Phytochemistry, Mechanisms, and Translational Perspectives
Pseudomonas aeruginosa is a major opportunistic pathogen associated with nosocomial infections, antimicrobial resistance, and persistent biofilm formation, highlighting the need for alternative therapeutic strategies. This review critically evaluates the current evidence on the phytochemistry, antimicrobial, antibiofilm, anti-inflammatory, and wound-healing properties of Aloe vera (Aloe barbadensis Mill.) against P. aeruginosa. Relevant peer-reviewed literature from major scientific databases was examined to summarize the phytochemical constituents of A. vera, their proposed mechanisms of action, therapeutic applications, safety considerations, and emerging approaches, including nanotechnology and computational drug discovery. The available evidence indicates that anthraquinones, polysaccharides, flavonoids, and related phytochemicals contribute to antibacterial activity, inhibition of biofilm formation, modulation of host inflammatory responses, and promotion of wound healing. However, considerable variability in phytochemical composition, limited pharmacokinetic and toxicological data, lack of standardized formulations, and insufficient high-quality preclinical and clinical studies continue to hinder clinical translation. Overall, A. vera represents a promising source of adjunctive antimicrobial and anti-virulence compounds for the management of biofilm-associated P. aeruginosa infections. Future research should prioritize phytochemical standardization, mechanistic validation, pharmacokinetic evaluation, and well-designed animal and clinical studies to support the development of safe and clinically effective A. vera-based therapeutics.
- 20 August 2026
- Published by MDPI AG in Preprints.org
Open AccessRecent Advances in Aloe vera as a Therapeutic Strategy Against Drug-Resistant Pseudomonas aeruginosa: Phytochemistry, Mechanisms, and Translational Perspectives
Pseudomonas aeruginosa is a major opportunistic pathogen associated with nosocomial infections, antimicrobial resistance, and persistent biofilm formation, highlighting the need for alternative therapeutic strategies. This review critically evaluates the current evidence on the phytochemistry, antimicrobial, antibiofilm, anti-inflammatory, and wound-healing properties of Aloe vera (Aloe barbadensis Mill.) against P. aeruginosa. Relevant peer-reviewed literature from major scientific databases was examined to summarize the phytochemical constituents of A. vera, their proposed mechanisms of action, therapeutic applications, safety considerations, and emerging approaches, including nanotechnology and computational drug discovery. The available evidence indicates that anthraquinones, polysaccharides, flavonoids, and related phytochemicals contribute to antibacterial activity, inhibition of biofilm formation, modulation of host inflammatory responses, and promotion of wound healing. However, considerable variability in phytochemical composition, limited pharmacokinetic and toxicological data, lack of standardized formulations, and insufficient high-quality preclinical and clinical studies continue to hinder clinical translation. Overall, A. vera represents a promising source of adjunctive antimicrobial and anti-virulence compounds for the management of biofilm-associated P. aeruginosa infections. Future research should prioritize phytochemical standardization, mechanistic validation, pharmacokinetic evaluation, and well-designed animal and clinical studies to support the development of safe and clinically effective A. vera-based therapeutics.
- Open Access
- 24 November 2025
- Published by MDPI AG in Proceedings
- Vol. 130 (1) , 24
Computational and Experimental Validation of Aloe Vera Against Pseudomonas Aeruginosa PsrA in Interventive Antibacterial Therapeutics
Background: Pseudomonas aeruginosa, a multidrug-resistant pathogen, employs biofilm formation as a key virulence strategy, complicating treatment
- 24 November 2025
- Published by MDPI AG in Proceedings
- Vol. 130 (1) , 24
Open AccessComputational and Experimental Validation of Aloe Vera Against Pseudomonas Aeruginosa PsrA in Interventive Antibacterial Therapeutics
Background: Pseudomonas aeruginosa, a multidrug-resistant pathogen, employs biofilm formation as a key virulence strategy, complicating treatment